top of page
추상적인 검은 파도
GR-topbg copy.jpg
recombinant Botulinum Toxin concept image

Recombinant Botulinum Toxin

Setting a new benchmark for next-generation toxin therapies through recombinant BoNT engineering

Targeted mRNA Delivery

We advance next-generation gene therapies through targeted mRNA delivery and in vivo CAR-T innovation.

The Next Frontier in Biotech

MVRIX is a biotechnology company focused on advancing new possibilities beyond the limits of conventional medicines.

main_bg01.png

The Next


Frontier


in Biotech

MVRIX는 첨단 바이오 기술을 통해 기존 의약품의 한계를 뛰어넘어 새로운 가능성을 열어가는 혁신적인 연구를 수행하는 기업입니다

We advance next-generation gene therapies through targeted mRNA delivery and in vivo CAR-T innovation.

We advance next-generation gene therapies through targeted mRNA delivery and in vivo CAR-T innovation.

We go beyond existing limits

to provide better choices

through Innovative R&D

3

Platform Technology

80 +

Patents

(PCT included)

20 +

Collaborative partners

bg_maintech_exp.jpg

Our Core Science

Smarter Innovation

We lead the future of therapeutics with three protein-engineering platforms.

Science 01
Navibody Platform

A targeted mRNA delivery platform that enhances antibody–LNP specificity and improves production efficiency.

  • In vivo CAR-T

  • Navibody Service

Science 02
rBoNT Platform

A recombinant botulinum toxin platform based on engineered recombinant production, enabling faster and safer development.

  • Faster, Longer rBoNT(Cosmetics)

Science 03
Virucidal Platform

A virucidal platform based on validated rHDL production technology, designed to address enveloped viruses such as COVID-19, influenza, and mpox.

  • Anti-COVID-19

Latest News

MVRIX in motion

We capture and share the moments of change we are creating.

9/4/26
MVRIX Completes KRW 8 Billion Series B Investment
8/14/26
MVRIX Selected for Technology Innovation SME (Inno-Biz) Certification
6/16/26
MVRIX participates in BIO2026
3/17/26
Navibody platform technology published in ACS Nano (DEC-205 receptor dual target)

Our Partners

Growing Synergy

MVRIX grows through strategic partnerships and collaboration.

Press Release

Reaching Further

Discover the latest updates from MVRIX.

default
MVRIX: "Precisely Targeting Invivo CAR-T with ‘Navibody’… Strengthening T-Cell Targeted Delivery"

9/28/26

약업신문

default
MVRIX, a developer of in vivo CAR-T therapy, raises 8 billion won in Series B investment

9/4/26

한국경제

default
MVRIX “Accelerates Development of mRNA-LNP ‘Invivo CAR-T’”… Pursuing 8 Billion Won Series B

5/26/26

더바이오

default
Catching cancer cells that evade immune cell attacks… Development of dual-target mRNA cancer vaccine

3/24/26

동아사이언스

bottom of page